74
Participants
Start Date
November 17, 2017
Primary Completion Date
February 15, 2022
Study Completion Date
February 15, 2022
PF-06835375
Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
Placebo
Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
Altoona Center for Clinical Research, Duncansville
PAREXEL International - EPCU Baltimore, Baltimore
Rheumatology Express, Catonsville
Carolina Phase 1 Research, LLC, Raleigh
Avail Clinical Research, DeLand
Omega Research Maitland, LLC, Orlando
Larkin Hospital, South Miami
Qps Mra, Llc, South Miami
Qps-Mra, Llc, South Miami
Clinical Research of West Florida, Inc., Clearwater
Private Practice of Robert W. Levin, MD, Clearwater
Pinnacle Research Group, LLC, Anniston
Pinnacle Research Group, LLC, Anniston
Metroplex Clinical Research Center, Dallas
MPP Infusion Centers, Dallas
Prive aftercare, Los Angeles
Wallace Rheumatic Studies Center, Beverly Hills
Lead Sponsor
Pfizer
INDUSTRY